NasdaqGS - Nasdaq Real Time Price USD

Solid Biosciences Inc. (SLDB)

8.54

-0.23

(-2.62%)

At close: April 25 at 4:00 PM EDT

8.54

+0.02

(+0.29%)

After hours: April 25 at 4:00 PM EDT

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to two newly hired employees. These grants were made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and were made as an inducement material to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule

GlobeNewswire 22 days ago

SLDB
-2.62%
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.

Zacks 23 days ago

SLDB
-2.62%
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. – – Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 – CHARLESTOWN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for SGT-003,

GlobeNewswire 24 days ago

SLDB
-2.62%
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

Solid Biosciences is shrugging off several messy years in gene therapy development. The biotech stock has gotten a triple-digit boost.

Investor's Business Daily 28 days ago

SLDB
-2.62%
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET. A live webcast of the presentation will be available on the Events page of the I

GlobeNewswire 29 days ago

SLDB
-2.62%
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2026 — — FDA cleared IND and granted Fast Track Designation and Orphan Drug Designation for Duchenne muscular dystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trial expected Q2 2024 — — Company entered into non-exclusive licensing agreement for use of its proprietary

GlobeNewswire last month

SLDB
-2.62%
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy (FSHD). The AAV-SLB101 caps

GlobeNewswire last month

SLDB
-2.62%
Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Leerink Partners Global Biopharma Conference – Miami, FL1x1 meetings on March 11, 2024Barclays 26th Annual Global Healthcare Conference – Miami, FLBo Cumbo, Solid’s President and Chief Executive Officer, will present on Wednesday, Mar

GlobeNewswire last month

SLDB
-2.62%
14 Stocks With Heavy Insider Buying In 2024

In this article, we will take a detailed look at 14 Stocks With Heavy Insider Buying In 2024. For a quick overview of such stocks, read our article 5 Stocks With Heavy Insider Buying In 2024. Markets await latest inflation numbers and the debate regarding soft vs hard landing is expected to persist in the Wall Street for months […]

Insider Monkey last month

SANA

TNYA

VOXX
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.

Zacks 3 months ago

ALLK

SLDB
-2.62%
VRTX
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Zacks 3 months ago

SLDB
-2.62%
PBYI

SRPT
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has been granted orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy candidate. “Obtaining ODD status

GlobeNewswire 3 months ago

SLDB
-2.62%
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Zacks 3 months ago

SLDB
-2.62%
CTMX
-1.84%
PBYI
Solid Biosciences Announces $109 Million Private Placement

CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement, which is expected to close on or about January 11, 2024, subject to the satisfaction of customary closing conditions.

GlobeNewswire 3 months ago

SLDB
-2.62%
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

CHARLESTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:45 am PT. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking

GlobeNewswire 3 months ago

SLDB
-2.62%
While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most

Key Insights The considerable ownership by private equity firms in Solid Biosciences indicates that they collectively...

Simply Wall St. 4 months ago

SLDB
-2.62%
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Zacks 4 months ago

SLDB
-2.62%
PTCT
Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

– Next-generation gene transfer therapy to treat Duchenne receives FDA Fast Track Designation – CHARLESTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003, the company’s next-generation Duchenne muscular dystrophy (Duchenne) gene therapy cand

GlobeNewswire 4 months ago

SLDB
-2.62%
Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by click

GlobeNewswire 5 months ago

SLDB
-2.62%
The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Zacks 5 months ago

ACLX

SLDB
-2.62%
VRTX

Performance Overview

Return	SLDB	S&P 500
YTD	+39.09%	+5.84%
1-Year	+77.55%	+22.03%
3-Year	-88.79%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Solid Biosciences Inc. (SLDB)

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

Solid Biosciences to Participate at Upcoming Investor Conferences

14 Stocks With Heavy Insider Buying In 2024

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

While institutions invested in Solid Biosciences Inc. (NASDAQ:SLDB) benefited from last week's 68% gain, private equity firms stood to gain the most

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

Performance Overview